DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Bowlus C, Neff G, Aspinall R. , et al.
Efficacy and safety of Seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study.
Hepatology 2018;
68: 1445A
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.